Transformative Therapies for Autoimmune Disease
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $95M
Founded date: 2021
Investors 2
| Date | Name | Website |
| 24.06.2021 | Lightspeed... | lsvp.com |
| 21.07.2021 | T1D Fund | t1dfund.or... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.06.2021 | Series A | $95M | - |
Mentions in press and media 5
| Date | Title | Description |
| 06.05.2022 | With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB | Michel Vounatsos → Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive efficacy questions. The highl... |
| 24.06.2021 | VC Daily: Abata Therapeutics Gets $95 Million, Takes Aim at Multiple Sclerosis | Good day. Third Rock Ventures has led a $95 million financing for Abata Therapeutics, a biotechnology startup seeking to treat a stage of multiple sclerosis that has no approved medication. Multiple sclerosis, which damages material that pr... |
| 23.06.2021 | Abata Therapeutics Launches with $95M Series A | BOSTON, MA, Abata Therapeutics has launched with $95 million in Series A funding led by Third Rock Ventures. >> Click here for more funding data on Abata Therapeutics >> To export Abata Therapeutics funding data to PDF and E... |
| 23.06.2021 | Third Rock-backed Abata gets $95M to take cell therapy to MS, other autoimmune diseases | Imagine an autoimmune disease treatment that activates only at the site of disease, shuts down inflammation from multiple sources, promotes tissue repair, and lasts for years. The source of this therapy, a type of immune cell, is already in... |
| - | Third Rock-backed Abata gets $95M to take cell therapy to MS, other autoimmune diseases | Imagine an autoimmune disease treatment that activates only at the site of disease, shuts down inflammation from multiple sources, promotes tissue repair, and lasts for years. The source of this therapy, a type of immune cell, is already in... |